PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 5, 2026Neural Regeneration Research0 citationsOpen Access

Neuroinflammation and noradrenergic modulation with β2-adrenoceptors: Emerging therapeutic targets for Parkinson’s diseases

View Full Paper
MTMaria Micaelle Gomes TavaresMCMilena Caroline Nunes Monteiro de CarvalhoMMMylaine Santos Mendonça

Key Points

  • Examine the roles of neuroinflammation and noradrenergic modulation in the progression of Parkinson’s disease.
  • Discuss structural and functional aspects of the locus coeruleus-noradrenergic system.
  • Examine the impact of glial activation and immune communication on neurodegeneration.
  • Analyze the differing effects of β-blockers and β2-adrenoceptor agonists.
  • β-blockers are linked to increased neuroinflammation and higher Parkinson’s disease risk.
  • β2-adrenoceptor agonists show potential neuroprotective effects.
  • Modulation of microglial phenotypes and reduction of α-synuclein aggregation were noted with β2-adrenoceptor agonists.

Abstract

Abstract Neurodegenerative disorders, such as Parkinson’s disease, are strongly influenced by neuroinflammatory processes and dysfunction of the locus coeruleus-noradrenergic system. The locus coeruleus-noradrenergic system plays a pivotal role in modulating neuroinflammation and maintaining homeostatic regulation in the central nervous system. This review discusses the structural and functional aspects of the locus coeruleus-noradrenergic system and its interaction with immune responses. We examine how neuroinflammation contributes to disease progression, with a focus on glial activation and peripheral-central immune communication. Additionally, we analyze the impact of β-adrenoceptor-targeting drugs, highlighting the contrasting roles of β-blockers and β2-adrenoceptor agonists in neurodegeneration. While β-blocker, particularly non-selective agents like propranolol, have been associated with exacerbated neuroinflammation and Parkinson’s disease risk, β2-adrenoceptor agonists demonstrate neuroprotective effects by modulating microglial phenotypes, reducing α-synuclein aggregation, and enhancing neurotrophic support. Finally, we explore the canonical and non-canonical β2-adrenoceptor signaling pathways implicated in neuroprotection. Collectively, this review supports β2-adrenoceptors as promising therapeutic targets and underscores the need for further studies to elucidate their mechanistic roles in modulating neurodegenerative processes.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Tavares et al. (2026) studied this question.

synapsesocial.com/papers/69843398f1d9ada3c1fb0daahttps://doi.org/10.4103/nrr.nrr-d-25-00903
Ask AI
Helpful
Bookmark
Share
View Full Paper